Joerg Herrmann MD
Professor of Medicine, Mayo Graduate School of Medicine, Rochester, MinnesotaDr. Joerg Herrmann received his medical training at Ruhr University, Bochum, Germany, and completed his internship in internal medicine at the University Clinic in Essen. Following a postdoctoral research fellowship, he pursued the clinician–investigator track in internal medicine-cardiology, and further training in interventional cardiology at the Mayo Clinic, Rochester, Minnesota. He then joined the staff of the Department of Cardiovascular Diseases at the Mayo Clinic, Rochester. Currently, he is a Professor of Medicine at the Mayo Graduate School of Medicine and serves as the director of the Cardio-Oncology Clinic and the research director of the Ischemic Heart Disease program.
Dr. Herrmann has been receiving NIH research funding, serves as a reviewer for over 30 journals, including all major cardiovascular journals. He currently is the chair of the Scientific Committee of the International Cardio-Oncology Society and an associated editor of several journals including the European Heart Journal (EHJ), EHJ Open, Trends in Cardiovascular Medicine, International Journal of Cardiology, Frontiers in Cardiovascular Medicine, and Current Cardiology Reports. He is also a regular contributor to Braunwald's Heart Disease, the associated editor of Trends in Cardiovascular Medicine, and the editor of the Cardio-Oncology Companion Book to Braunwald’s Heart Disease as well as the textbook Clinical Cardio-Oncology.
His main research interests are cardio-oncology, cardiac biomarkers, periprocedural myocardial infarction, atherosclerosis, and vascular biology.
Disclosures
Dr. Joerg Herrmann participated in the 2014 and 2016 Ponatinib in CML Cardio-Oncology Advisory Board meeting organized by ARIAD Pharmaceuticals, the 2016 Carfilzomib Advisory Board meeting organized by Amgen and is a member of the Institute for Cardio-Oncology advisory panel sponsored by Bristol-Myers Squib. He also reports disclosures from Pfizer.
Recent Contributions to PracticeUpdate:
- Magnetic Navigation Proves to Be Useful Adjunct to PCI Intervention
- Electrocardiographic Changes With Normal Stress Echocardiography
- Multiparametric CMR Detects Cardiac Allograft Vasculopathy
- Geographic Variation in Use of PCI for Stable Ischemic Heart Disease After the COURAGE Trial
- Treatment Planning Using Virtual Coronary Stenting and Computed FFRactional Flow Reserve
- Long-Term Outcomes Based on Coronary Anatomy and Stenting Technique With DES for Unprotected Left Main CAD
- 2-Year Safety and Efficacy of First- or Second-Generation Drug-Eluting or Bare Metal Stents
- 2013 Top Stories in Cardiology: Atherosclerosis
- Biomarkers for Predicting Cardiotoxicity in Breast Cancer
- Outcome Impact of Coronary Revascularization Strategy Reclassification With Fractional Flow Reserve at Time of Diagnostic Angiography: Insights From a Large French Multicenter Fractional Flow Reserve Registry